On Oct 28, major Wall Street analysts update their ratings for $HCA Healthcare (HCA.US)$, with price targets ranging from $396 to $460.
Morgan Stanley analyst Craig Hettenbach maintains with a hold rating, and adjusts the target price from $427 to $406.
Barclays analyst Andrew Mok CFA maintains with a buy rating, and maintains the target price at $396.
TD Cowen analyst Ryan Langston maintains with a buy rating, and adjusts the target price from $450 to $440.
RBC Capital analyst Ben Hendrix maintains with a buy rating, and maintains the target price at $405.
Truist Financial analyst David S Macdonald maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $HCA Healthcare (HCA.US)$'s main analysts recently are as follows:
The performance of HCA Healthcare was anticipated to encounter disruptions due to hurricanes. A 'bigger surprise', however, was the projection for EBITDA and EPS in 2025, which fell below market expectations and ended a streak of strong financial outperformances. Despite the allure of the stock's recent 9% decline, there is a belief that it may enter a phase of consolidation.
HCA Healthcare's third-quarter results demonstrated resilience, overcoming the negative impacts of hurricanes, which are anticipated to persist into the fourth quarter and push full-year 2024 guidance towards the lower end. Despite these ongoing challenges, the company's management anticipates earnings growth in 2025 to meet or exceed its long-term objectives, supported by an admissions growth forecast of 3%-4%, which is considered above the usual trend.
The firm revised its model after evaluating HCA Healthcare's third-quarter results. Despite high anticipations for the quarter, the company delivered a robust underlying performance, evidenced by a 7.1% increase in same-store revenues compared to the previous year's third-quarter comparison of 7.9%.
HCA Healthcare's Q3 results aligned with market expectations, influenced by solid same-store volumes and increased Medicaid DPPs, which balanced out the interruptions caused by hurricanes. Following the earnings announcement, the company's stock experienced a significant drop, which is thought to be a result of projected EBITDA for 2025 slightly trailing market estimates, a market shift in anticipation of the upcoming election, and a perception of high valuation.
Here are the latest investment ratings and price targets for $HCA Healthcare (HCA.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
